https://www.selleckchem.com/pr....oducts/avelestat-azd
vestigate whether these markers of subclinical cardiovascular disease can be modified to reduce the risk of cardiovascular disease in CKD. In CKD, increases in NT-proBNP were significantly associated with greater risk of incident HF and AF, and increases in sST2 were associated with HF. Further studies should investigate whether these markers of subclinical cardiovascular disease can be modified to reduce the risk of cardiovascular disease in CKD. Digital and mobile health (mHealth) technologies improve patient-provider commun
Like
Comment
Share
